LC-MS/MS Characterization of Xyloside-primed Glycosaminoglycans with Cytotoxic Properties Reveals Structural Diversity and Novel Glycan Modifications
Overview
Authors
Affiliations
Structural characterization of glycosaminoglycans remains a challenge but is essential for determining structure-function relationships between glycosaminoglycans and the biomolecules with which they interact and for gaining insight into the biosynthesis of glycosaminoglycans. We have recently reported that xyloside-primed chondroitin/dermatan sulfate derived from a human breast carcinoma cell line, HCC70, has cytotoxic effects and shown that it differs in disaccharide composition from nontoxic chondroitin/dermatan sulfate derived from a human breast fibroblast cell line, CCD-1095Sk. To further investigate the structural requirements for the cytotoxic effect, we developed a novel LC-MS/MS approach based on reversed-phase dibutylamine ion-pairing chromatography and negative-mode higher-energy collision dissociation and used it in combination with cell growth studies and disaccharide fingerprinting. This strategy enabled detailed structural characterization of linkage regions, internal oligosaccharides, and nonreducing ends, revealing not only differences between xyloside-primed chondroitin/dermatan sulfate from HCC70 cells and CCD-1095Sk cells, but also sialylation of the linkage region and previously undescribed methylation and sulfation of the nonreducing ends. Although the xyloside-primed chondroitin/dermatan sulfate from HCC70 cells was less complex in terms of presence and distribution of iduronic acid than that from CCD-1095Sk cells, both glucuronic acid and iduronic acid appeared to be essential for the cytotoxic effect. Our data have moved us one step closer to understanding the structure of the cytotoxic chondroitin/dermatan sulfate from HCC70 cells primed on xylosides and demonstrate the suitability of the LC-MS/MS approach for structural characterization of glycosaminoglycans.
Fluorescently labeled xylosides offer insight into the biosynthetic pathways of glycosaminoglycans.
Mastio R, Willen D, Soderlund Z, Westergren-Thorsson G, Manner S, Tykesson E RSC Adv. 2022; 11(60):38283-38292.
PMID: 35498069 PMC: 9044174. DOI: 10.1039/d1ra06320k.
Persson A, Nikpour M, Vorontsov E, Nilsson J, Larson G Mol Cell Proteomics. 2021; 20:100074.
PMID: 33757834 PMC: 8724862. DOI: 10.1016/j.mcpro.2021.100074.
Analysis of the Glycosaminoglycan Chains of Proteoglycans.
Song Y, Zhang F, Linhardt R J Histochem Cytochem. 2020; 69(2):121-135.
PMID: 32623943 PMC: 7841699. DOI: 10.1369/0022155420937154.
Entchev E, Jantzen I, Masson P, Bocart S, Bournique B, Luccarini J PLoS One. 2020; 15(5):e0233032.
PMID: 32413051 PMC: 7228089. DOI: 10.1371/journal.pone.0233032.
Gomez Toledo A, Pihl J, Spliid C, Persson A, Nilsson J, Ayres Pereira M Glycobiology. 2020; 30(12):989-1002.
PMID: 32337544 PMC: 7724742. DOI: 10.1093/glycob/cwaa039.